Related Experiment Video
Updated: Sep 20, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
The effects of hyperbaric oxygen therapy and mitochondrial transplantation on cisplatin toxicity
Volkan Tekin1, Zehra Çiçek1, Gizem Esra Koç2
1Department of Physiology, Gülhane Faculty of Medicine, University of Health Sciences, General Doktor Tevfik Sağlam Cad., 06010 Etlik, Keçiören, Ankara, Türkiye.
Abstract:
Cisplatin is an effective chemotherapeutic agent with dose-limiting toxicity in non-target tissues. Hyperbaric oxygen therapy (HBOT) and mitochondrial transplantation (MitoTr) have been explored as supportive strategies in preclinical models. We examined whether HBOT and/or MitoTr modulate cisplatin-associated reductions in MTT metabolic activity and oxidative balance in healthy human mesenchymal stem cells (hMSCs) under incubator versus hyperbaric conditions. Bone marrow-derived hMSCs were seeded at 5 × 103 cells/well and exposed to cisplatin at an experimentally determined MTT-based LD50 (148 μM; 150 μM used). A delayed adjunctive intervention protocol was applied after LD50-level exposure: cisplatin or vehicle for 24 h, followed by 4 h MitoTr co-incubation (10× or 100× cell-number-scaled dose), then three HBOT sessions (90 min, 2.1 ATA) or matched incubator control. Endpoints were MTT absorbance (NAD(P)H-dependent oxidoreductase activity), total antioxidant status, total oxidant status, and oxidative stress index, analyzed by two-way ANOVA with Tukey post hoc. At 150 μM cisplatin, MTT absorbance was markedly reduced in all cisplatin-containing groups under both conditions (all p < 0.001 vs controls), and neither HBOT nor MitoTr restored MTT signal to control levels. Among cisplatin-free groups, M10 under HBOT exceeded control HB MTT absorbance (p = 0.009), whereas M10 under incubator conditions did not differ from control. HBOT reduced baseline MTT absorbance in cisplatin-free groups relative to matched incubator controls (p < 0.001). MitoTr lowered oxidant status under incubator conditions; HBOT improved redox indices in mitochondria-free groups. Under the LD50-level conditions tested, neither HBOT nor MitoTr restored NAD(P)H-dependent oxidoreductase (MTT) activity in hMSCs. Under non-toxic conditions, both modalities produced context-dependent redox changes. Whether lower, clinically relevant cisplatin exposures would yield partial protection remains an open question.
Related Concept Videos
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...